KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Current Taxes (2016 - 2022)

Historic Current Taxes for Pacira BioSciences (PCRX) over the last 9 years, with Q2 2022 value amounting to $11000.0.

  • Pacira BioSciences' Current Taxes changed N/A to $11000.0 in Q2 2022 from the same period last year, while for Jun 2022 it was $11000.0, marking a year-over-year change of. This contributed to the annual value of $429000.0 for FY2021, which is 27631.58% up from last year.
  • As of Q2 2022, Pacira BioSciences' Current Taxes stood at $11000.0.
  • Pacira BioSciences' Current Taxes' 5-year high stood at $1.7 million during Q1 2020, with a 5-year trough of $11000.0 in Q2 2022.
  • In the last 5 years, Pacira BioSciences' Current Taxes had a median value of $343000.0 in 2019 and averaged $534200.0.
  • Over the last 5 years, Pacira BioSciences' Current Taxes had its largest YoY gain of 197051.28% in 2020, and its largest YoY loss of 9144.79% in 2020.
  • Quarter analysis of 5 years shows Pacira BioSciences' Current Taxes stood at $90000.0 in 2018, then skyrocketed by 1381.11% to $1.3 million in 2019, then plummeted by 91.45% to $114000.0 in 2020, then skyrocketed by 276.32% to $429000.0 in 2021, then plummeted by 97.44% to $11000.0 in 2022.
  • Its Current Taxes was $11000.0 in Q2 2022, compared to $863000.0 in Q1 2022 and $429000.0 in Q4 2021.